Dorsey & Whitney Trust CO LLC Has $485,000 Stock Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Dorsey & Whitney Trust CO LLC increased its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 2.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,594 shares of the medical equipment provider’s stock after purchasing an additional 102 shares during the quarter. Dorsey & Whitney Trust CO LLC’s holdings in Zimmer Biomet were worth $485,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the stock. Janney Montgomery Scott LLC grew its holdings in Zimmer Biomet by 181.0% during the 3rd quarter. Janney Montgomery Scott LLC now owns 25,869 shares of the medical equipment provider’s stock worth $2,793,000 after acquiring an additional 16,663 shares during the last quarter. Atria Investments Inc grew its holdings in Zimmer Biomet by 60.2% during the 3rd quarter. Atria Investments Inc now owns 5,429 shares of the medical equipment provider’s stock worth $586,000 after acquiring an additional 2,041 shares during the last quarter. Mesirow Financial Investment Management Inc. grew its holdings in Zimmer Biomet by 95.2% during the 3rd quarter. Mesirow Financial Investment Management Inc. now owns 5,254 shares of the medical equipment provider’s stock worth $567,000 after acquiring an additional 2,563 shares during the last quarter. Covestor Ltd grew its holdings in Zimmer Biomet by 36.3% during the 3rd quarter. Covestor Ltd now owns 1,088 shares of the medical equipment provider’s stock worth $117,000 after acquiring an additional 290 shares during the last quarter. Finally, Ashton Thomas Securities LLC bought a new stake in Zimmer Biomet during the 3rd quarter worth approximately $28,000. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the stock. Barclays reduced their target price on shares of Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating on the stock in a report on Monday, February 10th. Royal Bank of Canada reduced their price objective on shares of Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating on the stock in a research note on Friday, February 7th. Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a research note on Friday, February 7th. Raymond James reduced their price objective on shares of Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating on the stock in a research note on Friday, February 7th. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $140.00 price objective on shares of Zimmer Biomet in a research note on Friday, February 7th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $124.15.

Zimmer Biomet Stock Performance

ZBH opened at $110.08 on Tuesday. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. The company’s fifty day moving average price is $105.65 and its two-hundred day moving average price is $107.13. Zimmer Biomet Holdings, Inc. has a 1-year low of $97.69 and a 1-year high of $133.90. The company has a market cap of $21.91 billion, a price-to-earnings ratio of 24.74, a PEG ratio of 1.95 and a beta of 1.04.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same quarter in the prior year, the business earned $2.20 EPS. On average, analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be issued a dividend of $0.24 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a $0.96 annualized dividend and a yield of 0.87%. Zimmer Biomet’s payout ratio is 21.57%.

Insiders Place Their Bets

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the company’s stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total transaction of $150,649.20. Following the transaction, the senior vice president now owns 8,768 shares in the company, valued at approximately $915,379.20. This represents a 14.13 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.95% of the company’s stock.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.